VRCA
Verrica Pharmaceuticals Inc. NASDAQ Listed Jun 15, 2018$5.76
+2.13%
vs $5.64
Mkt Cap $61.4M
52w Low $3.28
37.9% of range
52w High $9.82
50d MA $6.30
200d MA $5.91
P/E (TTM)
—
EV/EBITDA
—
P/B
2.5x
Debt/Equity
0.1x
ROE
-72.3%
P/FCF
-3.4x
RSI (14)
44.50
ATR (14)
$0.49
Beta
1.43
50d MA
$6.30
200d MA
$5.91
Avg Volume
52.7K
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
44 West Gay Street · West Chester, PA 19380 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2026 | AMC | -0.43 | -0.56 | -30.2% | 6.26 | -1.6% | -1.8% | -0.7% | +1.0% | +2.3% | -9.5% | — |
| Nov 14, 2025 | AMC | -1.14 | 0.13 | +111.4% | 3.93 | -2.3% | -5.1% | +2.7% | +17.0% | -10.3% | +4.7% | — |
| Aug 12, 2025 | AMC | -0.70 | 0.02 | +102.9% | 6.82 | +3.4% | -3.4% | -6.7% | -3.1% | +3.4% | -1.8% | — |
| May 13, 2025 | AMC | -1.40 | -1.00 | +28.6% | 5.50 | +0.0% | -2.7% | +20.0% | +3.1% | -2.7% | -0.2% | — |
| Mar 11, 2025 | AMC | -0.25 | -0.24 | +4.0% | 6.48 | -2.9% | -7.6% | -1.3% | -9.1% | +21.2% | -0.2% | — |
| Nov 4, 2024 | AMC | -0.37 | -0.49 | -32.4% | 14.30 | -35.0% | -44.2% | -6.5% | -5.6% | +17.9% | +15.9% | — |
| Aug 14, 2024 | AMC | -0.43 | -0.31 | +27.9% | 31.20 | +7.1% | -6.7% | -3.8% | +5.7% | -4.4% | +2.8% | — |
| May 13, 2024 | AMC | -0.54 | -0.38 | +29.6% | 95.60 | +4.0% | -0.7% | -4.1% | +0.5% | -5.2% | +0.3% | — |
| Feb 29, 2024 | AMC | -0.47 | -0.48 | -2.1% | 52.70 | +2.8% | +5.3% | +0.0% | -7.4% | -3.3% | -2.2% | — |
| Nov 9, 2023 | AMC | -0.22 | -0.32 | -45.5% | 32.10 | -0.9% | -4.2% | -2.1% | -2.7% | +8.2% | +9.5% | — |
| Aug 8, 2023 | AMC | -0.22 | -0.21 | +4.5% | 52.90 | +0.4% | +4.3% | -3.1% | -2.6% | -2.9% | -1.4% | — |
| May 9, 2023 | AMC | -0.20 | -0.13 | +35.0% | 65.40 | +2.1% | -0.2% | -2.8% | -3.1% | -0.8% | -2.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 26 | H.C. Wainwright | Reiterates | Buy | $12 | $6.06 | $6.30 | +4.0% | -0.7% | +0.7% | -0.3% | -4.6% | +2.4% |
| Dec 18 | Brookline Capital | Upgrade | Hold → Buy | — | $8.05 | $8.69 | +8.0% | +0.7% | -3.6% | +1.2% | +3.8% | +1.5% |
| May 14 | Needham | Maintains | Hold → Hold | — | $5.50 | $5.50 | +0.0% | -2.7% | +20.0% | +3.1% | -2.7% | -0.2% |
| Apr 9 | Needham | Maintains | Hold → Hold | — | $5.79 | $5.77 | -0.3% | -20.0% | -4.3% | +9.3% | +14.3% | -10.8% |
| Apr 8 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $6.45 | $6.51 | +0.9% | -10.2% | -20.0% | -4.3% | +9.3% | +14.3% |
| Mar 12 | Needham | Maintains | Hold → Hold | — | $6.48 | $6.29 | -2.9% | -7.6% | -1.3% | -9.1% | +21.2% | -0.2% |
| Dec 20 | Needham | Maintains | Hold → Hold | — | $6.76 | $6.80 | +0.6% | +2.7% | +1.4% | -2.6% | -5.4% | +5.4% |
| Nov 6 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $7.98 | $8.36 | +4.8% | -6.5% | -5.6% | +17.9% | +15.9% | -4.4% |
| Nov 5 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $14.30 | $9.30 | -35.0% | -44.2% | -6.5% | -5.6% | +17.9% | +15.9% |
| Oct 21 | TD Cowen | Maintains | Buy → Buy | — | $16.00 | $16.00 | +0.0% | -1.9% | +1.3% | -5.0% | -0.7% | +0.7% |
| Oct 4 | RBC Capital | Maintains | Outperform → Outperform | — | $14.50 | $14.70 | +1.4% | -9.7% | +2.3% | -4.5% | +0.0% | +0.8% |
| Oct 3 | Needham | Downgrade | Buy → Hold | — | $11.10 | $11.00 | -0.9% | +30.6% | -9.7% | +2.3% | -4.5% | +0.0% |
| Oct 2 | Brookline Capital | Downgrade | Buy → Hold | — | $13.70 | $13.60 | -0.7% | -19.0% | +30.6% | -9.7% | +2.3% | -4.5% |
| Aug 15 | RBC Capital | Maintains | Outperform → Outperform | — | $31.20 | $33.40 | +7.1% | -6.7% | -3.8% | +5.7% | -4.4% | +2.8% |
| Aug 15 | Needham | Maintains | Buy → Buy | — | $31.20 | $33.40 | +7.1% | -6.7% | -3.8% | +5.7% | -4.4% | +2.8% |
| May 16 | Needham | Maintains | Buy → Buy | — | $91.00 | $89.70 | -1.4% | +0.5% | -5.2% | +0.3% | +0.8% | +3.2% |
| May 14 | Needham | Maintains | Buy → Buy | — | $95.60 | $99.40 | +4.0% | -0.7% | -4.1% | +0.5% | -5.2% | +0.3% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $95.60 | $99.40 | +4.0% | -0.7% | -4.1% | +0.5% | -5.2% | +0.3% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $70.50 | $69.10 | -2.0% | +2.0% | -1.7% | -2.8% | +0.7% | +1.2% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $52.70 | $54.20 | +2.8% | +5.3% | +0.0% | -7.4% | -3.3% | -2.2% |
| Mar 1 | Needham | Maintains | Buy → Buy | — | $52.70 | $54.20 | +2.8% | +5.3% | +0.0% | -7.4% | -3.3% | -2.2% |
| Dec 15 | Jefferies | Maintains | Buy → Buy | — | $37.60 | $42.00 | +11.7% | +62.0% | -8.7% | +0.0% | +1.3% | +13.9% |
| Nov 10 | Needham | Maintains | Buy → Buy | — | $32.10 | $31.80 | -0.9% | -4.2% | -2.1% | -2.7% | +8.2% | +9.5% |
| Oct 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.40 | $37.70 | +0.8% | -2.4% | +0.0% | -0.3% | -0.5% | -0.8% |
| Aug 23 | Needham | Maintains | Buy → Buy | — | $43.70 | $44.10 | +0.9% | +1.4% | -1.6% | +3.0% | +0.4% | -0.2% |
| Aug 10 | Needham | Maintains | Buy → Buy | — | $55.20 | $55.50 | +0.5% | -3.1% | -2.6% | -2.9% | -1.4% | -2.6% |
| Jul 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $53.10 | $55.80 | +5.1% | -2.4% | +11.6% | +1.0% | -3.9% | -4.1% |
| Jul 25 | Needham | Upgrade | Hold → Buy | — | $51.10 | $56.20 | +10.0% | +4.1% | -0.2% | -2.4% | +11.6% | +1.0% |
| Jul 25 | RBC Capital | Maintains | Outperform → Outperform | — | $51.10 | $56.20 | +10.0% | +4.1% | -0.2% | -2.4% | +11.6% | +1.0% |
| Jul 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $66.90 | $67.50 | +0.9% | +6.4% | -0.8% | +0.3% | +1.4% | +3.9% |
| Mar 22 | Jefferies | Maintains | Buy → Buy | — | $71.20 | $72.00 | +1.1% | -10.5% | -2.5% | +5.2% | -1.2% | +0.3% |
| Mar 7 | RBC Capital | Maintains | Outperform → Outperform | — | $72.70 | $72.10 | -0.8% | -7.7% | +1.6% | -3.1% | -0.8% | -1.4% |
| Feb 13 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $71.00 | $79.20 | +11.5% | +1.8% | -0.6% | +4.9% | -3.1% | +8.3% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.00 | $19.70 | -1.5% | -3.5% | -6.2% | +7.7% | +16.4% | +0.9% |
| May 25 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $55.60 | $26.10 | -53.1% | -63.8% | -2.5% | +2.0% | -3.5% | -6.2% |
| Mar 10 | Brookline Capital | Maintains | Buy → Buy | — | $79.60 | $80.70 | +1.4% | +0.4% | -1.4% | -2.4% | +3.6% | +0.6% |
| Mar 3 | Needham | Maintains | Buy → Buy | — | $85.90 | $88.30 | +2.8% | -1.9% | -3.4% | -5.7% | +0.3% | +3.4% |
| Sep 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $110.30 | $109.90 | -0.4% | +2.1% | +5.1% | -2.7% | +10.5% | -2.0% |
| Sep 21 | RBC Capital | Maintains | Outperform → Outperform | — | $120.30 | $92.50 | -23.1% | -8.3% | +2.1% | +5.1% | -2.7% | +10.5% |
| Sep 21 | Needham | Maintains | Buy → Buy | — | $120.30 | $92.50 | -23.1% | -8.3% | +2.1% | +5.1% | -2.7% | +10.5% |
| May 14 | RBC Capital | Maintains | Outperform → Outperform | — | $116.70 | $119.70 | +2.6% | +0.3% | +0.0% | -0.5% | -3.5% | -0.6% |
| Mar 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $136.80 | $142.10 | +3.9% | +5.7% | +4.4% | +13.8% | -2.5% | +1.0% |
| Feb 17 | Needham | Maintains | Buy → Buy | — | $140.50 | $141.20 | +0.5% | +9.8% | -5.3% | +2.0% | -1.4% | -4.0% |
| Jul 15 | BofA Securities | Downgrade | Buy → Neutral | — | $84.70 | $83.50 | -1.4% | -6.5% | +3.3% | +4.8% | -3.6% | -7.6% |
| Jun 30 | Needham | Maintains | Buy → Buy | — | $140.70 | $113.00 | -19.7% | -21.7% | -7.7% | +1.4% | -2.9% | -3.4% |
| Jun 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $140.70 | $113.00 | -19.7% | -21.7% | -7.7% | +1.4% | -2.9% | -3.4% |
| Jun 24 | Northland Capital Markets | Maintains | Outperform → Outperform | — | $151.20 | $154.70 | +2.3% | -7.3% | +3.1% | -1.8% | -0.8% | -21.7% |
| Mar 24 | Needham | Maintains | Buy → Buy | — | $79.90 | $85.00 | +6.4% | +33.8% | +6.0% | +2.9% | -4.4% | +2.4% |
| Feb 21 | H.C. Wainwright | Maintains | Buy → Buy | — | $111.20 | $111.20 | +0.0% | -0.3% | -2.4% | +1.8% | -2.2% | +0.8% |
| Jul 10 | Jefferies | Maintains | Buy → Buy | — | $197.90 | $200.00 | +1.1% | -6.3% | +0.5% | +0.1% | +1.2% | -2.4% |
No insider trades available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Velan Capital Investment Management Lp | 471,559 | $2M | — | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 188,758 | $999K | New | Mar 2026 |
| 3 | Jane Street Group, Llc | 101,722 | $845K | New | Dec 2025 |
| 4 | Marshall Wace, Llp | 140,497 | $743K | Added | Mar 2026 |
| 5 | Stonepine Capital Management, Llc | 99,735 | $528K | Reduced | Mar 2026 |
| 6 | Morgan Stanley | 44,018 | $366K | Added | Dec 2025 |
| 7 | Two Sigma Investments, Lp | 50,662 | $268K | Reduced | Mar 2026 |
| 8 | Renaissance Technologies Llc | 32,360 | $171K | Added | Mar 2026 |
| 9 | Northern Trust Corp | 31,580 | $167K | Added | Mar 2026 |
| 10 | Legacy Trust | 17,234 | $91K | — | Mar 2026 |
| 11 | Verdad Advisers, Lp | 12,098 | $64K | New | Mar 2026 |
| 12 | Beck Mack & Oliver Llc | 12,000 | $63K | — | Mar 2026 |
| 13 | Ubs Group Ag | 4,270 | $23K | Added | Mar 2026 |
| 14 | Capital Analysts, Llc | 1,500 | $8K | — | Mar 2026 |
| 15 | Royal Bank Of Canada | 965 | $5K | Added | Mar 2026 |
| 16 | New England Capital Financial Advisors Llc | 200 | $2K | — | Dec 2025 |
| 17 | Salomon & Ludwin, Llc | 290 | $2K | — | Mar 2026 |
| 18 | Fortitude Family Office, Llc | 127 | $672 | Reduced | Mar 2026 |
| 19 | Bnp Paribas Financial Markets | 110 | $582 | — | Mar 2026 |
| 20 | Pnc Financial Services Group, Inc. | 102 | $540 | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 7
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 28,182 | $154K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 11,139 | $61K | Feb 2026 |
| 3 | Fidelity Series Total Market Index Fund | 9,479 | $52K | Feb 2026 |
| 4 | Fidelity Nasdaq Composite Index Fund | 9,107 | $50K | Feb 2026 |
| 5 | Small Cap Core Fund | 1,607 | $9K | Mar 2026 |
| 6 | Avantis Total Equity Markets ETF | 481 | $3K | Feb 2026 |
| 7 | Knights of Columbus U.S. ALL CAP INDEX FUND | 27 | $187 | Jan 2026 |
Valuation
Market Cap
$61.4M
Enterprise Value
$29.8M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.06x
P/B
2.48x
P/S
1.65x
P/FCF
-3.40x
EV/EBITDA
—
Shares Out
10.7M
Financials (TTM)
Revenue
$37.2M
Net Income
-$17.8M
EBITDA
-$11.4M
Free Cash Flow
-$17.6M
Op Cash Flow
-$17.6M
EPS Basic
$-1.68
EPS Diluted
$-1.56
EPS Forward
$-1.44
Gross Margin
89.5%
Op Margin
-36.4%
Net Margin
-48.0%
Balance Sheet
Total Assets
$47.1M
Total Liab.
$22.4M
Total Equity
$24.7M
Cash
$30.1M
LT Debt
$0
Book Value/Sh
$2.32
Debt/Equity
0.07x
Current Ratio
2.59
Quick Ratio
2.45
Returns & Growth
ROE
-72.3%
ROA
-38.0%
ROIC
-38.0%
Rev Growth YoY
+370.2%
EPS Growth YoY
+88.6%
Price Returns
2W
-17.1%
1M
-9.6%
3M
+5.3%
6M
-36.7%
12M
+16.4%
Technicals
52W High
$9.82
52W Low
$3.28
50d MA
$6.30
200d MA
$5.91
RSI (14)
44.50
ATR (14)
$0.49
Beta
1.43
Avg Volume
53K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$17.00
High
$17.00
Low
$17.00
Median
$17.00
Data updated apr 27, 2026 8:04am
· Source: financialmodelingprep.com